LABLABHealthcare · Medical Devices

LAB Stock Forecast: Standard BioTools, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.64
+4.92% on the day

The median 12-month analyst price target for Standard BioTools, Inc. is $1.35. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 41 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$249.1M
Ticker Nerd rank
41/ 100
Median analyst target
$1.35
Analysts covering
1
Revenue$20.1M−7.6% y/y
Operating income−$7.8M
Net income−$26.8M
Free cash flow−$10.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
0.0%
YTD
−50.0%
1Y
−50.0%
From 52W high
−61.9%
From 52W low
+18.5%
$0.54
$1.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Standard BioTools, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
41/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
71
Revisions
66
Quality
60
Volatility
54
Accruals
41
Issuance
37
Value
20
Momentum
16

Growth (71): Sales and profits are climbing, and climbing faster than before.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.60$0.80$1.00$1.20$1.40$1.60$1.80Jan 26Apr 26Jul 26Oct 26LABHigh $1.35Median $1.35Low $1.35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$1.35
Low
$1.35
Median
$1.35
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Nov 2025TD CowenMaintainsHold$1.55 → $1.35
27 Feb 2025KeybancDowngradeSector Weight—
31 Oct 2024TD CowenMaintainsBuy—
1 Aug 2024TD CowenMaintainsBuy—
16 Apr 2024TD CowenInitiatesBuy—
4 Apr 2024JefferiesInitiatesBuy—
12 July 2023KeybancInitiatesOverweight—
27 Aug 2020UBSMaintainsBuy—
10 Aug 2020UBSMaintainsBuy—
6 Nov 2019Janney Montgomery ScottDowngradeNeutral—
18 Oct 2019UBSUpgradeBuy—
15 Mar 2019UBSInitiatesNeutral—
14 Mar 2019BTIGInitiatesBuy—
3 Jan 2019Janney Montgomery ScottUpgradeBuy—
2 Nov 2018Piper SandlerUpgradeOverweight—
5 Feb 2016Deutsche BankMaintainsBuy—
5 Feb 2016MizuhoUpgradeBuy—
20 Jan 2016Cowen & Co.DowngradeMarket Perform—
6 Jan 2016Avondale PartnersInitiatesMarket Outperform—
6 Jan 2016Deutsche BankInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LAB.

Market Radar

This page is one stock. Monday covers all of them.

LAB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Standard BioTools, Inc. returned −50.0% against +6.9% for the S&P 500, dividends included.

LAB vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26LABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.0×

Cheaper than 37% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
52.4%

Higher than 65% of US stocks

Operating margin
−56.0%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
−7.8%

Higher than 38% of US stocks

Return on assets
−5.0%

Higher than 32% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Standard BioTools, Inc. has a market value of $249.1M.

  • Revenue in the twelve months to 30 June 2026: $84.6M. The latest quarter shrank 7.6% year on year.

  • Net income over the same four quarters: $84.9M, a 100.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.22.

  • Free cash flow in the twelve months to 30 June 2026: −$82.6M.

  • Shares outstanding: 392.1M.

  • Standard BioTools, Inc. employs 385 people — $220K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LAB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LABStandard BioTools, Inc.$249.1M41
SSIISS Innovations International, Inc.$245.9M11
OFIXOrthofix Medical, Inc.$240.4M60
NPCENeuroPace, Inc.$267.7M73
CLPTClearPoint Neuro, Inc.$221.5M29
TMCITreace Medical Concepts, Inc.$274.6M55
INFUInfuSystem Holdings, Inc.$285.8M100

Take a look at LAB’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Standard BioTools, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LAB

What is the LAB stock price forecast for 2026-2027?

The median 12-month analyst price target for Standard BioTools, Inc. is $1.35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LAB stock a buy right now?

Of the 1 analyst covering Standard BioTools, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Standard BioTools, Inc. 41 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LAB?

As at 21 Nov 2026, Standard BioTools, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).

Will LAB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $1.35, and Ticker Nerd's factor model ranks Standard BioTools, Inc. 41 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LAB stock forecast for 2030?

No analyst covering Standard BioTools, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.35 to $1.35 over the next 12 months.

How has LAB stock performed over the past year?

Standard BioTools, Inc. returned -50.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Standard BioTools, Inc. do?

Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research. The company provides instrumentation, consumables, assays, software, and services used to study genes, proteins, cellular behavior, and tissue architecture across early discovery, translational, and clinical research workflows.

Company

About Standard BioTools, Inc.

Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research. The company provides instrumentation, consumables, assays, software, and services used to study genes, proteins, cellular behavior, and tissue architecture across early discovery, translational, and clinical research workflows. Its product portfolio includes platforms for genomics, single-cell analysis, spatial biology, mass cytometry, and microfluidics, supporting applications in areas such as oncology, immunology, and biomarker discovery. Standard BioTools serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations worldwide. The company focuses on helping researchers generate high-quality, reproducible biological data that can improve understanding of health and disease.

CEO Dr. Michael Egholm Ph.D. · 385 employees · United States · https://www.standardbio.com